Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Autolus reports robust Q4 performance, poised for CAR T therapy success

Autolus Therapeutics demonstrated strong operational and financial performance in Q4 2022, supported by key partnerships and successful clinical data for obe-cel.
While facing challenges in competitive positioning and pricing strategy, the company has opportunities to capitalize on upcoming milestones and data releases to drive growth.
By focusing on long-term data integrity and strategic market positioning, Autolus aims to establish obe-cel as a leading therapy in the CAR T landscape.

Autolus Therapeutics reports Q1 loss, highlights CAR T progress

Autolus Therapeutics showcased progress with CAR T programs and a strong financial position
The company's focus on Obe-cel and collaborations with key partners present growth opportunities
Challenges include data disclosure queries, program potential, and partnership considerations
Opportunities lie in extending runway, expanding collaborations, and exploring new indications

Autolus Therapeutics reports strong Q2 results and eyes market expansion

Autolus Therapeutics is on track with its lead program, Obe-cel, and is making strategic moves to enhance its product portfolio and operational capabilities.
The company's financial performance remains stable, with a focus on cost management and extending its cash runway into 2025 through milestone payments.
Despite facing challenges in expense management and regulatory processes, Autolus is well-positioned to capitalize on opportunities in new indications and product development.

Autolus Therapeutics reports strong Q3 earnings and pipeline advancements

Autolus Therapeutics is making significant progress with its pipeline programs, focusing on advancing obe-cel for autoimmune diseases and presenting data at ASH.
The company's strong financial position and anticipated milestones, such as BLA filing and AUTO8 program updates, provide a solid foundation for future growth.
While facing challenges in a competitive market and logistical hurdles for pivotal trials, Autolus has opportunities to differentiate its offerings and strengthen its position in new indications.

Autolus Therapeutics reports strong financials and strategic growth opportunities

Autolus Therapeutics had a successful year financially and operationally, well positioned with a cash reserve for upcoming milestones and program expansions.
While facing regulatory challenges and cost management considerations, the company is strategically focused on expanding its therapeutic opportunities and enhancing operational efficiency.
Opportunities lie in exploring new indications, streamlining patient enrollment processes, and leveraging partnerships for broader market access and growth.

Autolus reports robust Q1 earnings, poised for strategic growth

Autolus Therapeutics demonstrated strong financial performance with increased revenue and cash reserves, positioning the company well for upcoming milestones and commercialization efforts.
While facing challenges related to accounting matters and escalating operating expenses, Autolus remains well-prepared for the launch of obe-cel and future pipeline developments.
Opportunities lie in upcoming regulatory reviews, milestone conferences, and potential treatment regimen evolution in the autoimmune space, signaling a promising outlook for Autolus.

Autolus reports robust Q3 earnings, poised for growth and innovation

Autolus Therapeutics demonstrated strong financial performance and progress in its CAR T therapy programs in Q3 2024, supported by milestone payments and a robust manufacturing facility.
While well-capitalized and positively received by physicians, the company faces challenges in cost guidance, market access strategies, and pediatric trial outcomes.
Opportunities lie in upcoming milestones, pediatric market positioning, and operational efficiency improvements, positioning Autolus for continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna -

Moderna exercises option to license proprietary targeting technology from Autolus

- Bristol Myers Squibb to receive access to Autolus' RQR8 safety switch for use in cell therapy programs -

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System

Shares of AUTL have lost a third of their value over the past year. Sentiment in the autologous CAR-T space is improving as lead players successfully grow sales and scale up to meet demand.

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Olivia Manser - Director, IR Christian Itin - CEO Lucinda Crabtree - CFO Conference Call Participants Mara Goldstein - Mizuho Rob Andrews - William Blair Bill Jahangiri - Truist Gil Blum - Needham & Company Kelly Shi - Jefferies Chuan Hong - JPMorgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2022 Financial Results Conference Call. As a reminder, this conference call is being recorded.

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2022 Results - Earnings Call Transcript

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, August 4, 2022.

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair's Biotech Focus Conference 2022 at The St. Regis New York in New York City. Autolus' Chief Executive Officer, Dr. Christian Itin, will participate in a panel discussion on ‘Operationalizing Cell Therapies' on Tuesday, July 12 at 8.55 – 10.15 am ET (1:55 pm – 3.15 pm BST) and the Company will also be attending one-on-one investor meetings at the event.

Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 – 13, 2022

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma - AUTO1/22 demonstrates encouraging and durable responses in children ineligible for commercial CAR T product - Obe-cel shows high level of sustained clinical activity in B-NHL patients and first activity in Primary CNS Lymphoma

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from www.autolus.com. The AGM is scheduled to be held at The Studio, WestWorks, White City Place, London W12 7FQ on Tuesday, June 28, 2022, commencing at 8:00 a.m. BST.

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending the Jefferies Healthcare Conference at the Marriott Marquis in New York City. Autolus' Chief Executive Officer Dr. Christian Itin will participate in a Fireside Chat on Thursday, June 9 at 9.00 – 9.30 am ET (2:00 pm – 2.30 pm BST) and the Company will also be attending one-on-one investor meetings at the event.

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia - Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Nick Abbott - Wells Fargo Mara Goldstein - Mizuho Gil Blum - Needham Simon Baker - Redburn Operator Ladies and gentlemen, thank you for standing by and welcome to the Autolus Therapeutics First Quarter 2022 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Olivia Manser, Director of Investor Relations.

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q1 2022 Results - Earnings Call Transcript

- Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST -

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead gene therapy obecabatagene autoleucel (obe-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T therapy that is being investigated in the ongoing FELIX Phase 2 study of adult relapsed / refractory B-Acute Lymphocytic Leukemia (ALL).

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, May 5, 2022.

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus' leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia (ALL) patients.

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

- Wells Fargo Annual Biotech Forum on April 12 and 13 -

Autolus Therapeutics to Participate in Conferences During April 2022

Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call Transcript

- Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT - - Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT -

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022.

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

The heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Loses 22.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

- Andrew J. Oakley to retire in March 2022

Autolus Therapeutics announces retirement of chief financial officer and succession plan

- obe-cel has the potential to transform outcomes for adult ALL patients

News for Autolus Therapeutics Stock (AUTL)